The S&P 500 and Dow are pushing new highs as 2016 comes to a close in the wake of the U.S. presidential election. Although this tailwind has been incredibly strong, there are still companies holding back this rally.
24/7 Wall Street has picked out a few companies posting some of the largest losses for the past week. Some companies are hitting lows and creating huge shareholder losses. A few of these companies are looking to cash in on the huge rally by participating in secondary offerings and taking advantage of these higher prices. Although, this is a double-edged sword because share prices generally drop when companies plan to issue more shares.
We have included a little color on why each stock has lagged, as well as a recent trading history, consensus analyst price target and a 52-week trading range.
Horizon Pharma PLC (NASDAQ: HZNP) saw its shares take a big step back on Thursday after the company reported topline results from one of its late-stage trials. Specifically, the company announced that the Phase 3 trial, STEADFAST, evaluating Actimmune (interferon gamma-1b) for the treatment of Friedreich’s ataxia (FA) did not meet its primary endpoint compared with treatment with placebo.
As for the primary endpoint, Actimmune did not show a statistically significant change from baseline in the modified Friedreich’s Ataxia Rating Scale (FARS‐mNeuro) at 26 weeks. For those that don’t know what the FARS-mNeuro is, it is an exam-based rating scale that measures disease progression based on functional parameters such as speech, ability to swallow, upper and lower limb coordination, gait and posture.
Additionally, the secondary endpoints did not meet statistical significance. No new safety findings were identified on initial review of data other than those already noted in the Actimmune prescribing information for approved indications.
As a result, Horizon Pharma has determined that, based on the trial results, the FA development program will be discontinued, including the 26-week extension study and the long-term safety study.
The stock closed the week down 25% at $14.83. It has a Thomson Reuters consensus analyst price target of $28.50 and a 52-week trading range of $13.05 to $23.44.
Repros Therapeutics Inc. (NASDAQ: RPRX) saw its shares take a loss on Wednesday after the company provided a key U.S. Food and Drug Administration (FDA) update. The company participated in the industry presentation at the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting on Tuesday, but the results were not favorable.
As we have said time and time again, FDA decisions and clinical trial updates have the potential to make or break companies in the biotech and pharmaceutical industries. 24/7 Wall St. has outlined 10 Major FDA Decisions and Catalysts Expected in December.
The panel provided the FDA with advice regarding a clinical and regulatory path to approval for products, such as enclomiphene, in subjects with obesity-related hypogonadism who wish to maintain spermatogenesis. However, the panel voted 16 to five that the achievement of testosterone improvement while maintaining evidence of spermatogenesis was not sufficient, in and of itself, to provide evidence of clinical benefit.
Over the past week, shares dropped about 15% to close at $1.51. The consensus price target is $5.25, and the 52-week range is $0.80 to $3.48.
Clearside Biomedical Inc. (NASDAQ: CLSD) has updated its amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering. It is worth noting that as Clearside Bio has gotten closer to this offering, the expected price and number of shares have dwindled. The company now expects to price its 4.0 million shares at $9.00 per share, with an overallotment option for roughly an additional 600,000 shares. At this price the entire offering is valued up to about $41.4 million.
Shares dropped by 42% last week, ending the week at $9.00, with a consensus price target of $25.00 and a 52-week range of $5.65 to $25.00.